BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...
Epithelioma Treatment Market to reach USD 13.1 billion by 2035, driven by rising skin cancer cases and growing adoption of ...
Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, ...
Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new ...
By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...
Summary • Alpha Tau Medical Ltd. (DRTS) gained 5.36% in after-hours trading to reach $5.50 following an FDA submission ...
An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 5, 2026, Alpha Tau Medical announced it has submitted the first ...
Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission ...
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...
5d
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best stocks under $25 to buy now. Cantor Fitzgerald reaffirmed its ...
Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback